Cytori Therapeutics, Inc. Announces Closing of Financing

SAN DIEGO–(BUSINESS WIRE)– Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it has completed the previously announced sale of shares of its Series A 3.6% convertible preferred stock pursuant to a registered direct offering representing gross proceeds of approximately $13.5 million. The preferred stock is convertible into shares of Cytori’s common stock at the option of the investors at a conversion price of $0.52. Cytori also issued warrants to purchase an aggregate of 25,961,541 shares of Cytori’s common stock at an exercise price of $0.5771 per share in the offering.

This entry was posted in Investment Banking News: Q4 - 2014. Bookmark the permalink.